“It’s not looking good for the Xarelto plaintiffs’ bar,” writes the National Law Journal. Yesterday, “a jury came out with a defensive verdict in the second trial over the [Xarelto] blood thinner. That’s about a month after Johnson & Johnson and Bayer won the first bellwether trial over Xarelto.”
In the first trial, jurors deliberated for less than two hours before rendering their verdict on May 3. This time, the jury deliberated for about three hours.
The Institute for Legal Reform has highlighted the dangers associated with trial lawyer drug advertising, similar to the ads used in Xarelto litigation, which solicit potential plaintiffs. These ads can scare patients out of taking lifesaving medications.